At Evercrest Research, research is not a marketing word — it describes what we actually do. Our internal research program drives compound selection, synthesis protocol development, and the quality standards we apply to every batch we release.
BPC-157, TB-500, and related pentadecapeptide and thymosin analogs for musculoskeletal and soft tissue repair research. We maintain an ongoing catalog of peer-reviewed studies supporting each compound category we supply.
Ipamorelin, CJC-1295, GHRP-6, hexarelin, and related GH secretagogue peptides for endocrine and metabolic research. All GH axis compounds are tested for purity and receptor-binding site identity via MS fragmentation.
Semaglutide analogs, tirzepatide, and GLP-1 receptor agonist peptides for obesity and metabolic disease research applications. Supplied at research grade with full analytical documentation per lot.
Epithalon, Selank, Semax, and related telomerase-activating and neuropeptide compounds for longevity and cellular aging research. Synthesized under validated protocols and independently verified before release.
Representative studies from independent researchers. All compounds for research use only.
Our testing protocol is based on pharmaceutical industry standards adapted for research-grade compound supply. Every lot undergoes the same battery of tests before release.
We do not operate our own analytical laboratory. All testing is performed by independent, accredited third-party facilities with no financial interest in our results.
ISO/IEC 17025-accredited laboratory specializing in HPLC and mass spectrometry testing for research-grade peptide compounds. Used for primary purity and identity verification.
Specializes in endotoxin testing, sterility assays, and pharmaceutical-grade analytical services for bioactive peptide materials. Handles our USP <85> LAL endotoxin panels.
Independent analytical lab providing secondary verification testing and residual solvent analysis. Used for cross-validation on high-volume compound lots.
In addition to our quality assurance program, Evercrest Research supports and participates in ongoing research into peptide synthesis methodology and compound stability.
Ongoing study examining the degradation kinetics of lyophilized peptides under temperature and humidity stress. Partners: 2 academic institutions. Status: Data collection in progress, 2026.
Collaborative project with our partner laboratory to develop and publish HPLC reference method standards for commonly supplied research peptides. Target publication: 2027.
Internal validation comparing solid-phase synthesis protocols across three cGMP manufacturers. Evaluating lot-to-lot consistency for BPC-157 and TB-500 analogs. 3 lots per protocol analyzed.
All materials are supplied for in vitro laboratory research purposes only by qualified researchers and licensed professionals.
Pentadecapeptide analogs, thymosin fractions, and related tissue repair research compounds. Full COA on every lot.
Growth hormone releasing peptides (GHRPs), growth hormone releasing hormones (GHRHs), and receptor-specific secretagogue analogs.
GLP-1 receptor agonist analogs, GIP/GLP-1 dual agonists, and related metabolic research peptides.
Telomere-associated peptides, cytoprotective compounds, and cellular senescence research materials.
Nootropic peptide analogs, anxiolytic neuropeptides, and CNS research compounds for neuroscience applications.
Specific compound requests fulfilled through our certified synthesis partner network. Minimum quantities and lead times apply — contact for a quote.